Corcept Therapeutics Incorporated - Common Stock (CORT)
62.30
-2.30 (-3.56%)
NASDAQ · Last Trade: Apr 17th, 1:42 PM EDT
Detailed Quote
Previous Close
64.60
Open
64.60
Bid
62.25
Ask
62.38
Day's Range
62.28 - 65.40
52 Week Range
20.84 - 117.33
Volume
580,743
Market Cap
7.22B
PE Ratio (TTM)
50.65
EPS (TTM)
1.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,227,840
Chart
About Corcept Therapeutics Incorporated - Common Stock (CORT)
Corcept Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for patients with severe metabolic and psychiatric disorders. The company primarily specializes in the modulation of glucocorticoid signaling, a pathway that plays a key role in various diseases, particularly those characterized by chronic stress and inflammation. Corcept's lead product is designed to help patients suffering from conditions such as Cushing's syndrome, and the company is also engaged in research aimed at expanding its therapeutic applications to broader health issues. Through its dedication to advancing scientific understanding and developing effective therapies, Corcept aims to improve the quality of life for patients battling these challenging health conditions. Read More
A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that trade tariffs could add upward pressure to inflation in the short term and complicate the Fed's efforts to stabilize the economy.
NASDAQ:CORT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst performers in the branded pharmaceuticals industry.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer.
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT)
jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review (PFS-BICR).
Corcept currently trades at $58.76 and has been a dream stock for shareholders. It’s returned 434% since March 2020, blowing past the S&P 500’s 117% gain. The company has also beaten the index over the past six months as its stock price is up 35.8%.
Uncover the potential of CORCEPT THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation.
Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
